Innovations in Ventricular Assist Devices for End-Stage Heart Failure

The number of patients with end-stage heart failure (HF) continues to increase over time, but there has been little change in the availability of organs for cardiac transplantation, intensifying the demand for left ventricular assist devices (LVADs) as a bridge to transplantation. There is also a gr...

Full description

Saved in:
Bibliographic Details
Published inAnnual review of medicine Vol. 70; no. 1; pp. 33 - 44
Main Authors Miller, Robert J.H, Teuteberg, Jeffrey J, Hunt, Sharon A
Format Journal Article
LanguageEnglish
Published United States Annual Reviews 27.01.2019
Annual Reviews, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The number of patients with end-stage heart failure (HF) continues to increase over time, but there has been little change in the availability of organs for cardiac transplantation, intensifying the demand for left ventricular assist devices (LVADs) as a bridge to transplantation. There is also a growing number of patients with end-stage HF who are not transplant candidates but may be eligible for long-term support with an LVAD, known as destination therapy. Due to this increasing demand, LVAD technology has evolved, resulting in transformative improvements in outcomes. Additionally, with growing clinical experience patient management continues to be refined, leading to iterative improvements in outcomes. With outcomes continuing to improve, the potential benefit from LVAD therapy is being considered for patients earlier in their course of advanced HF. We review recent changes in technology, patient management, and implant decision making in LVAD therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0066-4219
1545-326X
DOI:10.1146/annurev-med-041217-011015